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EDITORIAL REVIEW
Atherosclerosis and arteriosclerosis in chronic renal failure
Cardiovascular complications are the principal cause of mor-
bidity and mortality in end-stage renal disease patients [1].
Arterial disease is the major underlying factor leading to myocar-
dial infarction and cerebrovascular events [2]. The alterations are
related to occlusive lesions usually due to growth of a thrombus at
the site of an atherosclerotic plaque. For these reasons, research
has concentrated on metabolic and mechanical factors of vascular
remodeling associated with atherosclerotic plaques.
There has been far less concern with the alterations of arteries
as vascular cushions. This is an important aspect, however, since
the function of arteries is not only to conduit blood, but also to
cushion the pulsation due to intermittent ventricular contraction
and flow generation [31. These two aspects of arterial function can
be dealt with independently since their functional alterations have
different origins and consequences. Disorders of conduit function
by narrowing the vessel lumen affect the tissues and organs
downstream, while disorders of cushioning function by arterial
wall stiffening have deleterious effects on the heart upstream [3].
In the present review we would like to introduce current hemo-
dynamic concepts of arterial function and its alterations in
end-stage renal disease.
Basic principles
The arterial system has two distinct and separate functions: to
deliver blood with minimal loss of mean pressure to bodily tissues
and organs, and to smooth the pulsations resulting from intermit-
tent cardiac ejection so that blood flow through these organs is
almost steady. The arteries thus act as conduits and as cushions
[3].
Conduit function of arteries
The efficiency of conduit function is related to the width of the
arteries and the near constancy of mean blood pressure along the
arterial tree, the mean pressure drop between the ascending aorta
and arteries in the forearm or leg being 2 to 3 mm Hg in a supine
position [3, 41. Alterations of conduit function occur through
narrowing or occlusion of arteries with restriction of blood flow
and resulting ischemia or infarction of tissues downstream. In
basal resting conditions the conduit function is maintained until
an artery is narrowed to 20% or less of its original diameter [51.
Atherosclerosis characterized by the presence of plaques is the
most common disease that disturbs conduit function. Atheroscle-
rosis is primarily an intimal disease, focal and patchy in its
distribution, occurring preferentially in the carotid bifurcation,
coronaries, renal arteries, infrarenal aorta, and femoral arteries
[6]. Focal compensatory enlargement of arterial lumen occurs at
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discrete sites of narrowing immediately adjacent to more or less
normal areas [7]. Risk factors and mechanisms of atherogenesis
are complex. They include smoking, lipid disturbances, thrombo-
genesis, production of vasoactive substances and growth factors
and mediators of inflammation. Besides these humoral factors
atherogenesis also depends on mechanical factors such as tensile
stress and alterations in shear stress [7—10]. Mechanical factors
exert their deleterious effects by several mechanisms including
increased permeability of endothelium to macromolecules and
activation of the endothelial layer by shear stress alterations. The
role of mechanical factors is confirmed by the high prevalence of
atherosclerosis in hypertension, with a predilection of atheroscle-
rotic plaques for certains sites characterized by disturbances of
flow pattern and shear stress, like orifices, bifurcations, bending or
pronounced tapering [6, 7].
Cushioning function of arteries
During systole around 50% of stroke volume is directly for-
warded into peripheral circulation, and other 50% is stored in the
aorta and major arteries, distending their walls and storing part of
the energy then available in the diastole. In diastole the stored
energy passively recoils the aorta, pressing the stored blood
volume forward into peripheral vessels. This so-called "Windkes-
sd function" transforms pulsatile flow in central arteries to almost
a steady flow in the tissues [3]. This cushioning function is very
efficient in young and healthy humans, and the extra energy lost
on account of the intermittent ventricular ejection is only 10 to
15% greater than if the heart's output were nonpulsatile and
continuous [11]. The efficiency of cushioning function depends
principally on the viscoelastic properties of arterial walls de-
scribed in terms of compliance, distensibility or stiffness (inverse
of distensibility) [3, 11]. The physical properties of arterial walls
will determine the amplitude of pressure waves, their propagation
and reflection along the arteries. Ejection of blood from the heart
into the aorta generates a primary pressure wave (incident), which
is propelled forward to other arteries throughout the body at a
given velocity (pulse wave velocity-PWV) [3, 11—13]. PWV in-
creases with arterial stiffening and therefore increases progres-
sively from the ascending aorta to the more distal parts of the
arterial tree. The incident pressure wave is reflected at any point
of structural or geometric discontinuity of the arterial tree,
generating a natural counterpulsation (reflected wave) traveling
backward from peripheral reflecting sites towards the ascending
aorta [12, 131. Incident and reflected waves are in constant
interaction, and they sum up to determine the amplitude and
shape of the measured pulse pressure wave, which depend on the
amplitude and phase relationship (the timing) between the com-
ponent waves. For a given pattern of ventricular ejection, the
amplitude and the timing of incident and reflected wave depend
on the viscoelastic properties of the arterial wall (arterial stiff-
ness). Arterial stiffening is associated with increased systolic and
pulse pressures, both directly by increasing the amplitude of the
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Fig. 1. Causes of death in patients aged  60 years at the start of treatment, starting RRT from 1983—1992 (selected countries). Comparison of mortality
factors in European countries with relatively high and low mortality rates, respectively. A small percentage of cardiogenic mortality is observed in some
countries with a relatively high mortality rate. Abbreviations are: St, standard patients; Diab, diabetic patients; PRD, primary renal disease; AUS,
Austria; SWE, Sweden; NOR, Norway; ITA, Italy; SPA, Spain; POR, Portugal. Symbols are: (LI) unknown; (till) accident; () miscellaneous; (L) social;() liver; (D) infection; (EI1) vascular; and (U) cardiac (from Valderrabano et al, Annual Report on Management of Renal Failure in Europe, XXV,
1994; oral presentation at the 23rd ERA-EDTA Congress, Athens, 11—14 June 1995; used with permission).
pressure wave and indirectly by increasing PWV, causing an early
return of reflected wave from the periphery to the aorta 3,
11—13]. The direct mechanism is responsible for an increased
pulse and systolic pressure in the entire arterial system. Because
of the different timing of wave reflections (reflection sites are
closer to peripheral arteries than to the aorta), the indirect
mechanism predominantly increases aortic and left ventricular
pressure in the late systole at the expense of mean diastolic
pressure, which is decreased [11, 13]. This results in increased
hydraulic load imposed on the left ventricle and a reduction in
subendocardial coronary blood supply during diastole 11—15].
Arteriosclerosis is the principal cause altering cushioning func-
tion [11]. Arteriosclerosis is primarily a medial degenerative
condition that is generalized throughout the thoracic aorta and
central arteries, causing dilation, diffuse hypertrophy and stiffen-
ing of arteries. Arteriosclerosis is sometimes considered as a
"physiological" aging phenomenon that is accelerated by hyper-
tension. Arteriosclerosis results in diffuse fibroelastic intima thick-
ening, an increase in medial ground substance and collagen, and
fragmentation of elastic lamellae with secondary fibrosis and
calcification of the media. These changes are more pronounced in
the aorta and central arteries than in the limb arteries [13].
Taken together, atherosclerosis is a disease that typically dis-
turbs conduit function almost exclusively, while arteriosclerosis
does not affect it. Nevertheless, in Western populations these two
conditions frequently coexist, since both progress with aging and
share several common pathogenetic mechanisms, making the
distinction between atherosclerosis and arteriosclerosis some-
times difficult. The development of ultrasound techniques has
permitted a direct visualization of small arterial wall segments
with direct evaluation of the extent of atheromatous plaques and
determination of arterial geometry, with measurements of arterial
diameters and intima-media thicknes in plaque-free segments.
Thus, the characteristics of arterial lesions at the site of athero-
matous plaques yield information concerning pathogenetic factors
that are very different from those at non-atherosclerotic sites.
Atherosclerosis in chronic renal failure
Prevalence and progression of atherosclerosis in uremic patients
Atherosclerosis is a frequent cause of morbidity in patients with
end-stage renal disease. Myocardial infarction and cerebrovascu-
lar events occupy an important place in the mortality of these
patients. This has already been shown in pioneer studies 20 years
ago [2, 16, 17] and led to the hypothesis of the existence of an
accelerated atherosclerosis [21. The high prevalence of cardiovas-
cular mortality in chronic hemodialysis patients reported in early
reports has been extensively confirmed by numerous subsequent
studies [1, 18—25]. Despite significant progress achieved with
dialysis technology, there is no evidence for a decrease in the
prevalence of atherosclerosis during the last decade, as shown in
a recent study by the ERA-EDTA Registry [1]. Based on this
report, the cardiovascular mortality rate of chronic dialysis pa-
tients, who were stratified into various subcategories according to
age, gender, and geographic origin, was approximately 20 times
higher than that of the general population, and the cerebrovas-
cular death rate was nearly 10 times higher. The relative risk was
thus considerably higher than that of nonuremic diabetic patients
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in whom the increase in risk is "only" threefold [261. Figure 1
shows the high prevalence of cardiovascular mortality in 60-year-
old dialysis patients in Europe. It is of interest that the well-known
north/south gradient of the general population was observed in
the dialysis population as well, that is, there appears to be a much
lower prevalence of lethal and non-lethal cardiovascular events in
southern Europe than in northern Europe [1]. An increase in the
relative risk to develop cardio- and cerebrovascular diseases was
also found in recent studies done in dialysis patients in the United
States [25, 27, 28], in Latin America [29], and in Japan [23, 30]. A
somewhat different conclusion was, however, reached in a recent
analysis by the USRD Annual Data Report of the trends in causes
of death in dialysis patients for the middle to late 1980s. It showed
that the adjusted death rates due to cerebrovascular accidents
actually decreased whereas that of cardiac causes increased [31].
It must be stressed that in most studies of cardiovascular mortality
no distinction has been made between ischemic and non-ischemic
causes. This is of importance since coronary artery-independent
mechanisms equally play important roles in the pathogenesis of
cardiac failure, including myocardial hypertrophy, valvular dis-
ease, intermittent or permanent extracellular volume overload,
and anemia [32, 33]. Interestingly, in a methodologically well-
done study from the most southern part of Japan [23], the
incidence of cerebrovascular events in hemodialysis patients was
extremely high (by a factor of 11.5 compared with the general
population), whereas that of the cardiac events was not increased
(factor 1.1). This incidence clearly is at variance with recent
observations made in the U.S. and in Europe.
The hypothesis by Lindner et a! [21 of an accelerated athero-
sclerosis in chronic dialysis patients has been continuously cited
since its publication two decades ago. Its validity appeared to be
supported by several subsequent reports. Thus, Ibels et a! showed
in a post-mortem study [34] that dialysis patients exhibited a
higher prevalence of atheromatous changes of the carotid and
femoral vessel wall, compared with age-matched subjects without
renal failure. Very recently, a similar finding has been reported
again in a large patient cohort from Japan, using an ultrasono-
graphic technique, in that there was an increased intima/media
thickness of the carotid artery in chronic hemodialysis patients,
compared with age-matched healthy control subjects (Fig. 2) [30].
However, it remains uncertain whether the atherosclerosis of
dialysis patients is effectively accelerated. The high cardiovascular
mortality rate is not a proof for an acceleration of the disease
process. Many dialysis patients have more or less marked vascular
lesions already at the start of dialysis treatment. The risk factors
present in the predialysis phase may be of primary importance.
Moreover, these patients often exhibit a number of coexistent risk
factors, such as arterial hypertension, dyslipidemia, glucose intol-
erance, and cigarette smoking. These risks clearly are additive. In
contrast, in the general population such risk factors may be more
often present as single, separate items. Therefore, the reality of
accelerated atherosclerosis remains subject to controversy [20, 35,
36]. In fact, this issue represents a preferred matter of discussion
at nephrology meetings [37].
Risk factors for atherogenesis in chronically uremic patients
Physical factors. (1.) Tensile stress—arterial hypertension. Evi-
dence that increased tensile stress is important in the pathogen-
esis of atherosclerosis comes from many observations including
the following: atherosclerotic plaques are virtually confined to
0
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Fig. 2. Intima/media thickness (IMD) of the carotid arteiy in healthy control
subjects (N = 81; L) and in chronic hemodialysis patients (N = 199; U).
Columns represent mean (± SD) values split up into different age groups.
Parentheses show numbers of subjects. < 0.001 versus control subjects;
< 0.05 versus control subjects (from Kawagishi et a!, Kidney Tnt
48:820—826, 1995, with permission).
systemic arteries where the tensile stress is high; the frequency of
atheromatous plaques is increased in patients with arterial hyper-
tension; in aortic coarctation, atherosclerosis is accelerated in
upper body arteries where the pressure is high, whereas it is
decreased in severity in lower body arteries where the pressure is
lower; and the development of atherosclerosis in autogenous vein
bypass grafts can be experimentally prevented by a rigid external
support that counteracts the increase in transmural pressure of
the graft [38]. It is not known how increased tensile stress
predisposes to atherosclerosis. It seems that high tensile stress
enhances the endothelial permeability to macromolecules,
thereby directly activating stress-sensitive ion channels.
Undoubtedly, hypertension plays an important role in the
pathogenesis of atherosclerosis and vessel alterations associated
with ischemia and hemorrhage [25]. A satisfactory control of
hypertension is associated with a significant decrease in cerebro-
vascular morbidity and mortality [39, 40]. The role of hyperten-
sion in the pathogenesis of ischemic heart disease is less well
established. In several studies, only a borderline effect of blood
pressure control, or even the absence of any effect, was observed,
whereas in other studies the control of hypertension was associ-
ated with an improvement of ischemic cardiac events [39, 40].
Hypertension is a frequent complication in chronic renal dis-
eases, occurring in 80% of patients with end-stage renal disease
before initiating dialysis therapy. After the start of dialysis treat-
ment hypertension persists in a large proportion of patients. In
particular, the physiologic blood pressure nocturnal dip is fre-
quently absent [41]. An association between high blood pressure
and occlusive vessel wall changes was found in chronic hemodi-
alysis patients [25, 42], and a rigorous control of hypertension
already at the time of incipient renal failure led to a significant
decrease of the incidence of myocardial ischemia after initiation
of dialysis therapy [43]. Clinical and epidemiological studies have
shown a high prevalence of isolated systolic hypertension in
ESRD patients [1, 44—46J. The systolic hypertension was associ-
ated with an increase in pulse pressure due to arterial stiffening. It
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is of note that in several epidemiological studies increased pulse
pressure has been found to be an independent and significant
predictor of myocardial infarction and coronary death [47, 481.As
discussed later, increased arterial stiffness could be a factor of
myocardial ischemia even in the absence of significant occlusive
atheromatous lesions.
(2.) Shear stress and alterations in blood flow. Changes in shear
stress may play a role in the pathogenesis of atherosclerosis, but
controversy exists whether low or high shear stress would affect
the development of atherosclerotic lesions. Fry [8] demonstrated
that increased blood flow velocity and wall shear stress enhanced
the permeability of the endothelial layers to macromolecules; this
can cause erosions of the endothelium and may result in vessel
wall injury. On the contrary, Caro and Nerem [9] suggested that
low shear stress may adversely affect the mass transport of lipids
across the endothelial layer consistently with the development of
atherosclerotic plaques at the sites of low shear stress like
bifurcations. Lower blood flow velocities and lower shear stress
result in a longer particle residence time at blood-vessel wall
interface, allowing greater interaction between blood and athero-
genie factors as well as facilitating the diffusion of lipids and
macromolecules accross the endothelium. Glagov and Zarins
suggested that low shear stress induces focal thickening of arterial
walls in order to reduce the local diameter and restore wall shear
stress [10]. The multiplicity of theories relating changes in shear
stress to atherogenesis illustrate the difficulty of measuring in vivo
the shear stress at the vascular interface in humans. Nevertheless,
it appears that fluctuating shear related to secondary non-laminar
and pulsatile flow is the major etiologic factor. The role of shear
stress alterations on the development of atherosclerosis in ESRD
patients has not been specifically investigated, principally due to
the difficulty of measuring the level of shear stress in humans.
Metabolic and humoral factors. (1.) Disturbances of lipid metab-
olism. The uremic syndrome is characterized by a number of
quantitative and qualitative derangements of lipoprotein metab-
olism. The resulting disturbances [49] should, at least theoreti-
cally, contribute to the pathogenesis of the atherosclerosis of
chronic renal failure.
The most important anomalies are: (1) an increase in the serum
levels of triglycerides, IDL, cholesterol-rich VLDL and apoli-
poprotein (apo) B, and apo-B containing lipoproteins consisting
of cholesterol-rich lipoprotein-B particles (LP-B) and triglyceride-
rich complex lipoprotein-B particles (LP-Bc); and (2) a decrease
in HDL-cholesterol (expecially HDL2), a decrease of the ratio of
apo-Al/apo-Cill, and a reduction of that of apo-Cli/apo-Clil
[49—51]. Apo-CIlI appears to be particularly important since
uremic patients with vascular disease have a significant increase in
the apo-Clil concentration of their B-lipoparticles, compared
with uremic patients free of vascular lesions [52]. Partially de-
graded triglyceride-rich LP-Bc has been shown to be strongly
associated with the development of small coronary artery athero-
sclerotic disease [53], whereas the level of cholesterol-rich LP-B
was associated with large coronary artery lesions [53, 54].
In addition, there are profound disturbances of the dynamics of
cholesterol transport, including a diminished cholesterol transport
rate in serum from HDL to VLDL and LDL [551 and an inhibition
of reverse cholesterol transport from peripheral cells to the
circulation [56]. Several factors are incriminated in these actions,
such as a decrease in LCAT enzymic activity [57] and the
accumulation of an inhibitor of the cholesterol ester transfer
protein (CETP) [58]. A decrease of the LDL receptor number at
the cell surface probably contributes to the abnormal lipoprotein
metabolism as well [59].
Furthermore, more recently several qualitative lipoprotein
changes have been shown to occur, including increased oxidation
[60—63], carbamylation [64], and transformation by advanced
glycation end-products (AGE) [651. Oxidative stress occurs not
only at the lipid level, but also at the protein level [66], and
hypochlorite-modified proteins, including oxidized LDL, are
present in human atherosclerotic lesions [671.However, it must be
stressed that there are conflicting data in the literature with
respect to excessive oxidation in uremia. Generally speaking,
oxidative processes favor the occurrence of atherosclerosis, prob-
ably via an interference with normal lipoprotein function and the
concomitant production of highly reactive lipid perioxidation
products, such as malonaldehyde, forming adducts with free
amino groups of lysines and other amino acids of apolipoprotein
B [68], and leading to enhanced generation of oxysterols and
depression of lipoprotein lipase mRNA and activity in arterial
foam cells [69]. A profound immunological response against
various epitopes of oxidized LDL generally occurs in patients with
atherosclerotic lesions [70, 71]. The identification of the specific
epitopes inducing this response probably will be assessable in the
near future with the help of natural monoclonal autoantibodies
[72].
Oxidized LDL may be taken up more readily in dialysis patients
than in healthy subjects because of an increased expression of type
I scavenger receptor [731. An enhanced formation of atheroma-
tous lesions ensues [74]. Similarly, AGE-LDL may be available for
uptake into the vessel wall to a larger extent than normal LDL
since such transformed particles have a prolonged stay in the
circulation [65]. Figure 3 shows the pathologically slowed clear-
ance of AGE-transformed LDL-particles in the experimental
animal, compared with that of native LDL particles. AGE-
transformed products of any nature, not only lipoproteins, might
participate in the genesis of vascular lesions, especially in diabetic
patients, via binding to their endothelial receptor, RAGE, the
induction of the vascular adhesion molecule VCAM-1 and the
attraction of circulating monocytes to the vessel wall [75]. Re-
cently, it could be shown that RAGE was expressed in arterial and
capillary endothelial cells of uremic patients, whereas it was not
constitutively expressed in endothelial cells sampled from non-
uremic control individuals [76].
The role of the triglyceride-rich lipoproteins as cardiovascular
risk factor remains controversial. However, hemodialysis patients
with coronary heart disease (CHD) generally have increased
serum triglyceride levels together with a diminished serum HDL-
cholesterol concentration [77]. The results of the CLAS study
showed that the progression of myocardial ischemia was associ-
ated with increased circulating levels of triglyceride-rich lipopro-
teins [78]. However, the relatively low degree of hypertriglyceri-
demia seen in the majority of uremic patients corresponds only to
a small increase in cardiovascular risk in the general population
without renal insufficiency [791. On the other hand, there is an
association between IDL, cholesterol-rich VLDL and the degree
of severity of CHD [801. In addition, the cholesterol-rich uremic
VLDL have a greater atherogenic potential than normal VLDL.
Furthermore, clinical conditions with an accumulation of residual
lipoparticles and IDL, such as those seen in chronic uremia,
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Fig. 3. Plasma clearance of native and AGL-transformed human LDL in
normal control mice (A) and in transgenic mice for the human LDL-receptor
(B). The animals were injected either native LDL (0) or AGE-LDL (•).
The control mice without the human LDL receptor exhibit a slow decrease
of native as well as of AGE-LDL (A). In contrast, the transgenic mice
were able to eliminate relatively rapidly native LDL, but not AGE-
transformed LDL. The latter therefore accumulate in serum (from Bucala
et al, PNAS 91:9441—9445, 1995; with permission).
represent an increased risk for the development of ischemic
cardiomyopathy [1041.
Only a small number of systematic studies have been done with
the most powerful, recently developed exploratory techniques to
test the hypothesis of an association between disturbances of
lipoprotein metabolism and atherosclerosis in a large population
of chronically uremic patients. In the majority of studies with a
sufficient sample size that are available to date, only serum levels
of total cholesterol and triglyceride levels have been measured for
this purpose, and it was found that in most of the patients who had
clinical evidence of vascular disease, serum triglycerides were
Serum levels
CVE+
(N = 16)
CVE-
(N = 43)
Triglycerides mM
Apolioprotein-B mg/liter
Apolipoprotein-ClI mg/liter
Apolipoprotein-Cill mg/liter
2.3 0.3
1.7 0.13
59 6
224 22
1.7 O.la
1.4 006b44 3
176 12
ap < 0.05; bp < 0.01
increased whereas serum total cholesterol was normal. This has
led to the conclusion that lipid disturbances probably do not play
an important role. However, a relationship between the anomalies
of lipoprotein metabolism and atheromatous vessel disease be-
—
come apparent whenever such anomalies are examined in an
300 appropriate manner. Hence, it has been shown recently that
dialysis patients with vascular disease had an increase in serum
triglycerides, total cholesterol, and VLDL cholesterol, compared
with patients who had no evidence of vascular disease [81].
However, the former also were approximately 15 years older than
the latter. Dialysis patients with type I diabetes and a history of
myocardial infarction had significantly higher serum levels of total
cholesterol and LDL/HDL-ratio than comparable patients with-
out myocardial infarction [26]. In a personal study done at our
institution in patients with advanced chronic renal failure who
were not yet on dialysis and who were matched for sex and age
(Lacour et al, unpublished study), we found significant differences
for several lipoprotein parameters between a group of patients
who had, and an another group who did not have, clinical
evidence of cardiovascular disease (Table 1). There was no
difference between the two groups with respect to age, body wt, or
plasma concentrations of total cholesterol, HDL cholesterol, apo
A or apo E.
In a recent study from Italy in which chronic hemodialysis
patients were examined using carotid ultrasonography, a signifi-
cant association was observed between the intima/media thickness
of the vessel wall and the serum concentration of LDL cholesterol
[82]. In contrast, in two other recent ultrasonographic studies
done in dialysis patients no association was found, based on
multivariate regression analysis, between the degree of severity of
atheromatous lesions of the carotid and the femoral artery and
the serum levels of a variety of lipid parameters, including apo-Al,
apo-B, total or HDL cholesterol, LDL cholesterol, and triglycer-
ides [30, 83]. Similarly, in a recent personal study (unpublished
results) no difference in commonly measured serum lipid levels
was observed between hemodialysis patients with or without
ultrasonographically-proven atheromatous plaques of the carotid
artery (Table 2). However, in none of these studies was a
comparison made between lipid parameters and clinically evident
cardio- or cerebrovascular events. Morover, the plaques could be
the result of long-standing lipid abnromalities that have been
changed with the advent of uremic or dialysis. For instance, the
serum level of total cholesterol decreases in the case of malnutri-
tion. Consequently, this parameter probably loses its predictive
value for vascular risk [84].
Another independent, genetically-determined vascular risk fac-
tor in the general population is the serum level of lipoprotein(a)
or Lp(a) [85]. However, its predictive value remains controversial
Table 1. Anomalies of serum lipids and apolipoproteins in chronically
uremic patients before the start of dialysis treatment who either had
(CVE +) or had not (CVE —) a history of cardiovascular events
a)
CoyEy CO
'
C
LL
a)
c.
:
U-
B
Time, minutes
1
0.1
0 100 200 300
Data are mean SD.
Abbreviations are: CCA, common carotid artery;
thickness; PWV, pulse wave velocity
ap < 0.01
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Table 2. Atheromatous plaques prevalence and comparison of clinical
parameters in ESRD patients
Parameters
Plaques absent
N = 45
Plaques presentN = 62
Age years 43.9 14.4 61.7 13.5
Sex M/F ratio 1.42 0.50 1.31 0.47
Body surface area m2 1.68 0.26 1.70 0.16
Systolic BP mm Hg 144.0 24.8 151.6 33.0
Diastolic BP mm Hg 87.0 13.9 78.6 14.6a
CCA diameter mm 5.91 0.79 6.64 0.87a
CCA JMT pm 722 107 838 87
CCA distensibility 21.5 9.5 12.9 6.4a
KPa1
Aortic PWV cm/second 908 163 1247 352
Total cholesterol mmol/liter 5.03 1.00 4.87 1.54
HDL cholesterol mmol/liter 1.07 0.35 1.12 0.47
Triglyceride mmollliter 1.90 0.98 1.93 0.87
Fibrinogen g/liter 4.20 0.88 5.67 1.OOa
Smoking status packet years 5.15 11.00 16.00 22.OOa
most important atherogenic factors associated with lipoprotein
metabolism.
(2.) Disturbances of glucose metabolism. Uremic patients suffer
from a variety of anomalies of carbohydrate metabolism. Insulin
resistance has been a well-known feature for many years. The
myocardial tissue is involved as well since insulin-dependent
glucose uptake is diminished in experimental uremia [26]. Insulin
resistance also is in part responsible for the disturbed activation of
lipoprotein lipase and the accumulation of VLDL and IDL in
renal failure. In the experimental animal, this anomaly can be
corrected by the administration of exogenous insulin [97]. It is also
frequently improved after the start of intermittent hemodialysis
treatment [98]. On the other hand, the increased glucose input
into the organism under CAPD treatment may have an athero-
genic potential via the induction of a variety of lipid disturbances,
such as an increase in the production of VLDL with hypertriglyc-
eridemia and a decrease in HDL cholesterol [99]. It is of note that
the recently described, so-called "metabolic syndrome" of patients
with essential hypertension, in particular in association with
obesity, relies on the hypothesis of a relationship between insulin
resistance and an increased tendency to develop atherosclerotic
vascular disease [100]. Hyperinsulinemia recently has been shown
to be an independent risk factor for ischemic heart disease [101].
It is well known that diabetic patients with advanced renal
failure have a mediocre vascular prognosis. This could be related
not only to the numerous metabolic anomalies linked to this
pathologic condition, but also to the induction of tissue damage
via slow, irreversible changes in extracellular molecules due to
hyperglycemia-induced covalent modification. The best studied
example of such changes is covalent modification of proteins by
advanced glycation end products (AGEs). The endothelial cell is
a primary target site. Reactive oxygen species, which may be
excessively formed in uremic patients, particularly under specific
hemodialysis conditions, contribute to sugar-adduct autoxidation
and AGE formation. Interestingly, inhibition of oxidant pathways
by antioxidants is capable of preventing intracellular AGE pro-
duction [102].
(3.) Hyperhomocysteinemia. Homocysteine can exert toxic ef-
fects on vascular endothelium via an acceleration of LDL au-
tooxydation [103] or via a mechanism favoring vascular thrombo-
sis [104]. Recently, homocysteine has also been shown to enhance
vascular smooth muscle cell proliferation, via an induction of
cyclin A [1051. Chronic renal failure is associated with an increase
in the plasma homocysteine level [106]. This is true for patients
before [107] as well as after the start of dialysis therapy [42, 108].
The increase generally persists after successful renal transplanta-
tion [1091. Hyperhomocysteinemia has been recognized as an
important vascular risk factor in the general population [110, 111].
Figure 5 demonstrates the prevalence of carotid artery stenosis as
a function of plasma homocysteine levels in non-uremic patients.
Recently, a similar relationship has been reported for hemodial-
ysis patients [42] and kidney graft recipients [109]. An insufficient
intake of folic acid could be the main cause of homocysteine
accumulation [1101. In addition, under hemodialysis treatment, a
state of relative folic acid deficiency can occur easily since folic
acid is a water soluble, dialyzable vitamin that is regularly cleared
during the dialysis session [1121. However, according to a recent
report only the total and the free forms, but not the reduced form,
of plasma homocysteine are increased in chronically uremic
patients [108], and only the reduced form is supposed to act as a
IMT, intima-media
[86]. Apparently, the risk increases in case other lipidic risk factors
are present, such as increased LDL, apoB, or decreased HDL [85,
87]. A correlation between low molecular apo(a)-phenotypes and
CHD has been found in several studies [881. The potential value
of serum Lp(a) as a risk factor has been examined in uremic
patients by numerous authors in recent years. In practically all
these studies an increase of serum Lp(a) was found in a more or
less large proportion of the patients examined [83, 89 —931. Figure
4 shows the increase of the percentage of uremic patients at our
institution with high serum Lp(a) levels, compared with age- and
sex-matched healthy control subjects [93]. This increase was
partially reversible after successful renal transplantation [93].
Moreover, a recent report showed that the serum Lp(a) concen-
tration was increased most often in hemodialysis patients with low
serum albumin levels, that is, in patients with malnutrition, as
compared to a normal serum Lp(a) concentration in dialysis
patients with normal serum albumin [94].
The increase of serum Lp(a) in end-stage renal disease appears
to be limited to patients with the high molecular isoform of the
various Lp(a) phenotypes [92]. In accord with the findings in the
population at large, higher serum Lp(a) concentrations were also
found in uremic patients with a history of ischemia [90, 91].
Surprisingly, a correlation existed on the one hand between the
serum level of Lp(a) and the number of ultrasonographically
demonstrated lesions of the carotid artery, and on the other hand
between the apo(a) phenotype and the presence of atheromatous
vessel changes [83].
The complex relationship between serum Lp(a) and atherogen-
esis in chronic renal failure requires further scrutiny [85, 86]. A
recently proposed mechanism for the induction or aggravation of
atheromatous lesions by Lp(a) is an impairment of vascular
relaxation by oxidized Lp(a) [95]. The latter may involve the
formation of 02— radicals, the production of which has been
shown by some groups to be enhanced in chronic renal failure
patients [96]. Enhanced oxidation not only occurs at the lipid
level, but also at the protein level [66]. Table 3 summarizes the
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pro-atherogenic factor. Another recent report found plasma
homocysteine levels to be elevated in many patients, despite
adequate blood folate levels, suggestive of an altered homocys-
teine metabolism (Note added in proof, A). Of note, an associa-
tion has recently been found in dialysis patients between total
plasma homocysteine and occlusive vascular disease [42]. It is
possible that in renal failure reduced plasma homocysteine is
formed in increased amounts which subsequently could be rapidly
oxydized [108], due to the increased oxydative stress activity in
uremia [96]. Interestingly, treatment with supraphysiologic doses
of folic acid, vitamin B6 and vitamin B12 can decrease or even
normalize plasma homocysteine levels in dialysis patients [113].
(4.) Cigarette smoking. The major role of cigarette smoking
needs not be discussed in any detail. Chronically uremic patients
are by no means protected against the deleterious effects of
tobacco consumption [30, 114].
Other potential risk factors. (1.) Disturbances of calcium and
phosphorus metabolism. Complicated atheromatous lesions with
vascular calcifications probably have a greater prevalence in
uremic than in non-uremic patients. Following percutaneous
transluminal catheter angioplasty (PTCA), the one-year reocclu-
sion rate was as high as 70% in dialysis patients, which is
considerably higher than in other patient categories with an
increased vascular risk, including non-uremic diabetic patients
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Table 3. Potentially atherogenic factors related to the disturbed
lipoprotein metabolism chronic renal failure
(1) Static quantitative and qualitative anomalies
Increase of the serum levels of:
—triglycerides
—intermediary lipoproteins (IDL)
—cholesterol-rich low-density lipoproteins (VLDL)
—apolipoprotein-B (apo-B)
—Lp(a)
* Decrease of the serum levels of:
—cholesterol in high-density lipoproteins (HDL-cholesterol)
—apo-Al/apo-Clil ratio
—apo-Cli/Apo-Cill ratio
* Physical changes of lipoproteins
—oxydation
—carbamylation
—transformation through "advanced glycation end-products" (AGE-
transformation)
(2) Dynamic anomalies
* Diminished reverse cholesterol transport
—decrease of LCAT, LPL and HTGL enzyme activities
—accumulation of an inhibitor of cholesterol ester transfer protein
(CETP)
4 6 8 10 12 14 16 18 20 22
Plasma homocysteine, imol/liter
Fig. 5. Age-corrected prevalence mtzximal extracranial carotid artery stenosis
of 25 percent in men () and women (S), as a function of quartiles of
plasma homocysteine concentration (from Seihub et a4 N Engl J Med
332:286—291, 1995; used with permission).
[26]. The calcification of atheromatous plaques probably is fa-
vored by an increased calcium-phosphate product, be it in asso-
ciation with secondasy hyperparathyroidism or with adynamic
bone disease. This is also true for the higher risk of developing
aortic valve calcification [115]. Recently, a significant relation was
also found in dialysis patients between the degree of carotid
intima/media thickness and the plasma levels of phosphate and
parathyroid hormone [301. Vascular calcifications may be favored
by long-term vitamin D therapy [116]. Clearly, a satisfactory
control of calcium and phosphate metabolism is mandatory not
only for an optimal skeletal stability but also with respect to
vascular risk. Finally, arterial hypertension also promotes vascular
calcium deposit, as has been recently shown for the coronary
artery in asymptomatic men [117].
(2.) Vitamin E deficiency. Several pieces of evidence have
emerged in favor of a potential enhancing role of vitamin E
deficiency in the occurrence of coronary heart disease of the
population at large [118, 119]. The protective role suggested from
these epidemiologic studies is in apparent contradiction with a
first large intervention study where the administration of vitamin
E for several years was not associated with a decrease in the
cardio- or cerebrovascular mortality of Finnish smokers in a
recently published intervention study [120]. However, the primary
end-point of that study was different, namely the prevention of
cancer. A recent randomized, controlled trial of vitamin E admin-
istration to patients with coronary heart disease concluded that
such a treatment substantially reduced the rate of non-fatal
myocardial infarction [121]. However, in that study there was no
apparent benefit on overall cardiovascular deaths either. Clearly,
further work will be required to show the patient groups for whom
these findings are applicable [121].
Vitamin E could afford protection against cardiovascular dis-
ease by several mechanisms, including antioxydative properties
allowing to limit lipoprotein oxydation [122], inhibitory effects on
platelet adhesion and aggregation [123] and on monocyte adhe-
sion to the endothelial cell [124], antiproliferative effects on
vascular smooth muscle [125] and intracellular effects on the
monocyte leading to a decreased ability to release oxygen radicals
and cytokines such as IL-lp [126]. To date, there is only limited
evidence in favor of a vitamin E deficiency state in uremic
patients. In one recent study there was no difference in the
vitamin E content of LDL between three uremic groups, including
patients either in the predialysis state, under hemodialysis, or
under CAPD treatment [631. However, subclass analysis of these
patients revealed that prolonged dialysis treatment was associated
with a decrease of the vitamin E content in LDL. The underlying
cause has not been elucidated. In particular, the possible role of
malnutrition has not been excluded. Since the efficiency of vitamin
E to protect uremic LDL against oxidation appears to be dimin-
ished, relatively high doses of the vitamin are likely to be required
to obtain that protection [63]. In another recent study, serum
vitamin E was not different between hemodialysis patients and
healthy subjects, although the content of tocopherol in red blood
cells and in HDL was lower in the dialysis patients [127].
(3.) Vasoactive, endothelium- and platelet-derived compounds.
Strictly speaking, endothelial and platelet dysfunction most often
is the consequence of the noxious action of many of the risk
factors that have been discussed, and not a risk factor by itself.
The vessel wall produces a variety of locally active vasoconstrictor
and vasodilator substances, some of which exert pro-atherogenic
or anti-atherogenic actions. The former include the endothelins,
and the latter several prostaglandin derivatives such as prostacy-
din and nitric oxide (NO or EDRF). The plasma level of
endothelin-1 is increased in uremic patients, before as well as
after the dialysis session [128, 1291. To what extent its increase in
the circulation reflects local endothelin-1 concentration and the
propensity to favor atheromatous changes of the vessel wall,
remains to be seen. Prostacyclin production by the vessel wall is
increased in chronic renal failure whereas the synthesis of throm-
boxane by platelets is diminished [130]. Enhanced synthesis and
activity of NO synthase leading to increased NO production has
been shown to occur with hemodialysis using cellulosic mem-
brane, but not polymethylmethacrylate membrane [131]. On the
other hand, the formation and retention of the competitive
inhibitor of NO synthase, asymetric dimethyl-L-arginine, may
favor a decrease in NO generation [132]. Furthermore, NO also
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could be more rapidly inactivated in dialysis patients, due to the
excessive generation of oxygen-derived free radicals [961. This
process is particularly pronounced in diabetics and can be re-
versed by administering the antioxidant, vitamin C [133]. It is of
note that hemodialysis patients may have a relative [134], and less
frequently an absolute [135], ascorbic acid deficiency. Collectively,
the physiologic equilibrium between locally formed vasoactive
compounds clearly is perturbed in the uremic state, either inter-
mittently or chronically.
A variety of other factors reflect an activation and/or dysfunc-
tion of the vascular endothelium in chronic renal failure in
association with changes of the coagulation system, such as
increased plasma levels of von Willebrand factor, plasminogen
activators, thrombomodulin, fibrinogen, proconvertin and the
inhibitor of type-i plasminogen activator [114, 136, 137].
(4.) Cytokines. Some cytokines such as interleukin-1 have been
ascribed pro-atherogenic actions as well [138]. The balance be-
tween IL-12 and IL-b production might contribute to the level of
immune-mediated tissue injury in atherosclerosis [139]. The en-
hanced generation of a variety of cytokines in uremic patients and
in particular the activation of monocytes and platelets through the
contact with bioincompatible dialysis membranes could favor
atherosclerosis, according to this hypothesis [26].
(5.) Miscellaneous factors. Estrogens exert a protective action
against the development of atheromatous vessel changes, proba-
bly not only via a more favorable constellation of plasma lipopro-
teins, but also via an inhibition of LDL-oxidation [140]. Estrogens
probably act in a similar way in uremic patients who frequently
exhibit a relative estrogen deficiency.
In the general population, angiotensinogen—and less convinc-
ingly the ACE enzyme—have been proposed to be two other risk
factors [861. However, a possible role of these factors has not yet
been demonstrated in chronic renal failure.
The vitamin B6 deficiency frequently observed in uremic dial-
ysis patients [112] could also favor the occurrence of atheroscle-
rosis, as is the case in non-renal patients in whom a negative
relation has been found between the plasma level of pyridoxal-5'-
phosphate (the co-enzyme of vitamin B6) and the prevalence of
extracranial carotid artery stenosis [110].
The progression from the advanced atherosclerotic lesion to
vessel occlusion involves neutrophil (PMN) adhesion to the
vascular endothelium. Neutrophils exert both scavenger and
damaging effects, via the increased expression of adhesion mole-
cules, including ICAM-1 and L-selectin. Neutrophil-depleted and
ICAM-1--deficient mice have been shown to be relatively resistant
to stroke [141]. In hemodialysis patients, neutrophil L-selectin
decreases during the dialysis session with cellulosic membrane
whereas plasma L-selectin increases, possibly in association with
pulmonary leukoaggregation and neutrophil activation [142].
Such intermittent changes of neutrophil function could have
relevance for the progression of atherosclerotic vessel disease.
Viral infections, which occur more frequently in urenlic patients
than in the general population, could play a role as well, as has
been seen with cytomegalovirus (CMV) or adenovirus infection,
possibly via the induction of vascular smooth muscle cell prolif-
eration secondary to changes of lipid metabolism, immunologic
injury, or impairment of vessel repair of atherosclerotic lesions
[143—145; Note added in proof, B]. Prior exposure to CMV
infection has been recently shown to be a strong independent risk
factor for restenosis after coronary angioplasty and atherectomy
[146].
The prolonged administration of immunosuppressive drugs
such as corticosteroids and cyclosporine also must be considered.
Both compounds may be atherogenic via their negative effects on
lipoprotein metabolism, that is an increase in circulating total
cholesterol and triglycerides [147].
Cyclosporine may also increase the development of atheroscle-
rotic lesions via its suppression of cell-mediated immunity [148].
In addition, cyclosporine has been suspected to exert a stimulating
effect on Lp(a), although a study done by our group failed to
confirm this contention, at least for the case of renal transplant
recipients [93].
Diuretics and antihypertensive drugs such as thiazides and beta
adrenergic receptor blockers also could theoretically be athero-
genie since they often induce an increase in serum triglyceride and
LDL-cholesterol concentration and/or a decrease in LPL activity
[149, 150]. Their positive effect in terms of blood pressure control
must, however, be regarded as more important than their poten-
tially negative effects via minor changes of lipoprotein metabolism
[1511.
The regular administration of heparin leads to a depletion of
the pools of the two major lipolytic enzymes, LPL and HTGL
through an intermittent liberation during each hemodialysis ses-
sion [152]. Moreover, heparin interferes with the action of the
third key enzyme of lipoprotein metablism, namely LCAT, via an
excessive liberation of free fatty acids. The use of low molecular
weight heparin is able to prevent such negative effects [153, 154].
Antiatherogenic mechanisms. (1.) Uremia and dialysis dependent
factors. As mentioned above, the predominance of locally synthe-
sized vasodilatory and antiatherogenic compounds such as pros-
tacyclin and NO theoretically should be protective against athero-
sclerosis. The same is true for the diminished liberation of
thromboxane and the mitogenic factor PDGF by platelets [26].
Anemia could be considered to be partially protective against
atherogenesis because anemia interferes with the interaction of
platelets with the arterial wall, decreasing platelet aggregation,
thereby decreasing the risk of thrombogenesis. However, in a
recent prospective study done in a large cohort of dialysis patients
anemia had no independent association with the development of
ischemic heart disease, whereas it was associated with clinical and
echocardiographic cardiac disease, as well as with overall mortal-
ity [155].
Vitamin A levels are often increased in chronic renal failure
[156]. Since the most common substrate of vitamin A is J3-caro-
tene, and since several epidemiological and animal studies suggest
that f3-carotene supplements are associated with a decreased risk
for coronary artery disease [157], one could speculate that uremic
patients are relatively protected via elevated plasma vitamin A.
However, in a recent randomized, double-blind, placebo-con-
trolled study the long-term supplementation of 22,071 physicians
with beta carotene had no effect on the incidence of cardiovascu-
lar disease [158]. Moreover, it must be stressed that in chronic
renal failure patients in whom the circulating vitamin A-binding
protein is increased, retinol-hinding protein is also elevated [159],
so that free plasma vitamin A levels are probably normal [160].
The frequently diminished plasma concentrations of the most
active vitamin D metabolite, calcitriol, which has been shown to
be proatherogenic, also might be considered to be a rather
favorable condition [26].
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Table 4. Atherogenic risk factors in chronic renal failure
(1) Generally recognized risk factors
—hypertension
—pathologically altered lipoproteins
—increased serum homocysteine levels
—cigarette consumption(2) Other potential risk factors
—disturbances of calcium phosphate metabolism
—vitamin E deficiency
—excessive local generation of pro-atherogenic substances
(angiotensinogen, endothelin-1, thromboxane B, cytokines)
—viral infections
—estrogen deficiency
drugs (antihypertensive and immunosuppressive agents, heparin)
(3) Potentially protective factors
—decreased formation of thromboxane, calcitriol
—increased liberation of prostacyclin
—biocompatible (versus bioincompatible) dialysis membrane
—moderate alcohol consumption (wine)
(4) Co-morbid states aggravating ischemia
—myocardial hypertrophy
—anemia
—hypotensive episodes during the dialysis session
—arteriovenous fistula with excessive blood flow rates
Table 5. Common carotid artery geometry and functional indexes in
ESRD and controls
Parameters
Controls
N = 55
ESRD
N = 107
Age years 48.4 14.9 54.4 16.9
Sex M/F ratio 1.41 0.50 1.37 0.49
Body surface area m2 1.84 0.24 1.68 020b
Systolic BP mm Hg 144.0 21.9 149.0 30.7
Diastolic BP mm Hg
CCA diameter mm
86.9 13.7
5.64 0.69
81.7 14.8a
6.37 0.91"
CCA IMT pin 720 88 794 liii'
CCA distensibility KPa 10' 21.4 10.9 15.9 8.7"
Aortic PWV cm/second 987 179 1117 340"
D1TI/STTI % 170.0 28.9 150 31.9"
Subjects with atheromatous plaques % 21.8 57.9"
Data are mean SD. Abbreviations are: CCA, common carotid artery;
IMT, intima-media thickness; PWV, carotido-femoral pulse wave velocity;
DTTI/S1T1, subendocardial viability index. This Table is from [145],
expanded data.
P <0.05; bp <0.01
The treatment of uremic patients with biocompatible, highly
permeable dialysis membranes could theoretically oppose athero-
genesis by exerting a positive influence on lipid metabolism, for
instance through an improved function of the LPL enzyme or a
decrease of apo-CIlI [161].
(2.) Uremia independent factors. To date, the regular, moderate
intake of alcohol, especially of wine, is considered by many
authors as a favorable measure against the development of
atheromatous lesions [162]. One of the various, as yet hypothet-
ical, mechanisms proposed in the literature is an inhibition of
LDL oxydation by phenolic substances contained in wine [1631.
Another possible mechanism is a decrease in platelet aggregation
[1641. The relatively high wine consumption in the southern part
of Europe compared with that in the northern part could explain,
at least in part, the north-south gradient of the prevalence of
atherosclerosis, which also has been found in dialysis patients
despite a much higher frequency of ischemic syndromes in the
latter [1]. However, reduced risk of coronary heart disease is also
seen with moderate consumption of other alcoholic beverages [165].
Reduced risk is observed only in individuals with increased LDL-
cholesterol levels, not in those with normal or low levels [166].
Table 4 summarizes the most important atherogenic risk factors
in chronic renal failure.
Arteriosclerosis in chronic renal failure
The arterial system in ESRD patients undergoes structural
remodeling very similar to changes with aging, and is character-
ized by diffuse dilation, hypertrophy and stiffening of the aorta
and major arteries (Table 5) [30, 167—169]. Although part of the
arterial alterations in ESRD patients are associated with the aging
process (Fig. 6), several features of arterial remodeling observed
in chronic uremia are different from those of the natural aging
process. Remodeling is an active process whose aim is to maintain
a constant tensile and/or shear stress. Arterial remodeling usually
occurs in response to long-term changes in hemodynamic (phys-
ical) conditions, in interaction with locally generated growth
factors, vasoactive substances and inflammatory mediators [170].
The endothelium plays a prominent role in the remodeling
process.
Hemodynamic factors of arterial remodeling in chronic uremia
Arterial walls and endothelial surface are exposed to the
influence of mechanical factors such as flow and pressure stresses.
Changes in blood flow and flow velocity alter the shear stress while
changes in pulsatile blood pressure alter the circumferential
tensile stress. Mechanical stresses alter the properties of arterial
wall leading to acute functional or chronic structural adaptive
changes [171—176].
Arterial changes associated with alterations in flow. Acute varia-
tions in flow and shear stress modulate arterial diameter through
the phenomenon of flow dependent vasodilation. When increased
during an augmentation in blood flow, shear stress induces an
adaptive and functional enlargement of the vessel radius that acts
as negative feedback to normalize the stress. This is accomplished
through shear stress release of nitric oxyde (endothelium-depen-
dent relaxing factor), hyperpolarizing factor and release of pros-
tacyclin [177—1801. A chronic increase in blood flow modulates the
vessel growth by inducing a structural enlargement of the arterial
caliber by the reorganization of vascular wall cellular and extra-
cellular components. Experimental studies have shown that re-
ductions in blood flow produced smaller arterial diameters and
medial tissue mass, while the creation of arteriovenous fistulas
and chronic increase in flow induced dilation of the arteries [171,
1721. In ESRD patients a similar effect of chronically increased
blood flow was observed in arteries of the arm bearing dialysis
fistula [1811. On the other hand, in ESRD, conditions such as
anemia, arteriovenous shunts and overhydration induce a state of
chronic volume/flow overload associated with increased systemic
and regional blood flow and flow velocity, creating conditions for
systemic arterial remodeling [169]. This has been illustrated by
cross sectional studies which showed a direct relationship between
the diameter of the aorta and of major arteries and blood flow
velocity [169], as well as by studies indicating that arterial enlarge-
ment could be limited by adequate fluid removal during dialysis
[168]. Therefore, it appears that the systemic arterial enlargement
observed in ESRD results in part from chronic volume and flow
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overload, and from this point of view differs from changes
observed during normal aging.
Arterial changes associated with increase in tensile stress. Tensile
stress is an important determinant of the vascular structure. A
chronic increase in tensile stress, such as that which occurs during
hypertension, induces vascular hypertrophy associated with an
increase in the arterial intima-media layer and a decrease in
lumen diameter, resulting in an increase in media/lumen ratio
[182, 183]. According to Laplace's law whereby wall tension is
directly proportional to arterial radius and intraarterial pressure,
and inversely proportional to wall thickness, hypertrophy compen-
sates for the increase in blood pressure or radius to maintain
normal stress. In comparison with non-uremic patients, the inti-
ma-media thickness of major central arteries is increased in
ESRD patients [169]. Like in the general population, in ESRD
patients arterial wall thickness increases with age, distending
pressure, and arterial diameter [169]. The increase in wall thick-
ness is proportional to changes in diameter, and this is a logical
consequence of Laplace's law, whereby wall tension is directly
proportional to arterial radius. Nevertheless, according to the
same law, when the blood pressure increases, and whatever the
internal radius, the wall-to lumen ratio should increase in order to
normalize the tensile stress. This is observed in nonuremic
populations where the wall-to-lumen ratio of arteries has been
reported to increase with intravascular pressure [182, 1831, but not
in ESRD patients [169]. The reason for this difference is not clear.
It is possible that conduit arteries have a limited capacity to
respond adequately to a combined flow and pressure overload.
This was observed on radial artey on the side of arteriovenous
fistula in ESRD patients [181] and in experimental conditions.
Indeed, in vein grafts subjected to separate mechanical factors
such as circumferential stretching and changes in blood velocity,
Dobrin, Littooy and Endean [1841 demonstrated that changes in
flow influence intimal thickening, whereas medial thickening
responds to changes in wall stress. Intimal thickening occurs in
response to low flow velocity, whereas medial thickening occurs in
response to increased parietal tension.
In ESRD, the increase in arterial intima-media thickness (Fig.
7) is associated with decreased arterial distensibility, increased
PWV, and early return of wave reflections [169]. Arterial disten-
sibility decreases with increasing blood pressure [3, 13]. In essen-
tial hypertensive patients, Laurent et al [185] have shown that the
decrease in arterial distensibility was primarily due to higher
distending blood pressure rather than to structural modifications,
and when adjusted for differences in blood pressure, hypertro-
phied arteries of essential hypertensive subjects were more dis-
tensible and had lower elastic modulus than those of normoten-
sive controls. In ESRD patients decreased arterial distensibility
results directly from arterial wall hypertrophy, and incremental
modulus of elasticity is increased in comparison with age- and
pressure-matched non-uremic controls [169]. The different rela-
tionship between hypertrophy and intrinsic elastic properties in
nonuremic subjects and ESRD points to qualitative differences in
the "hypertrophic process," being in favor of altered intrinsic
elastic properties as observed in experimental uremia and in vitro
in arteries of uremic patients, namely fibroelastic intimal thicken-
ing, calcification of elastic lamellae and ground substance depo-
sition [34].
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Fig. 6. Scatter plot showing the correlation
U
between age and common carotid artely (CCA)
diameter (A, r = 0.40; P < 0.0001) and CCA87 intima-media thickness (B; r = 0.58, P <
0.0001) in ESRD patients (from London et al,
Age, years Kidney mt 50:600—608, 1996, expanded data).
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Fig. 7. Scatter plot showing the correlations
____________________________
between CCA distensibility and left ventricular
I mass (A, r =
—0.33, P < 0.001) and CCA
8 1 6 24 32 intima-media cross sectional area and CCA
distensibility (B; r = —0.57, P < 0.0001) in
CCA intima-media ESRD patients (from London et al, Kidney mt
cross-sectional area, mm2 50:600 to 608, 1996, expanded data).
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Nonhemodynamic regulators of arteriosclerotic remodeling in ESRD
It is beyond the scope of the present review to provide a
detailed description of factors that modulate the growth of
vascular smooth muscle cells and mediators of remodeling in
extracellular matrix in general. Numerous growth factors and
inhibitors are implicated in the pathogenesis of both atheroscle-
rosis and arteriosclerosis. The role of some factors has already
been discussed in the section concerning atherogenesis. In ESRD
patients, the number of studies dealing specifically with the role of
growth promoters or inhibitors is limited, and usually concern
atherosclerosis and not arteriosclerosis. Recent studies performed
on endothelial cells in vitro have shown that uremic serum has a
direct effect on vascular subendothelium, characterized by a less
intricate network of fibrils of extracellular matrix, and by a
decreased attachment of endothelial cells to that matrix [186]. It
would be of interest to analyze the potential effect of active
vitamin D compounds on the mechanical properties of the vessel
wall. Experimental studies have shown that calcitriol enhances
resistance artery force generation in vitro [187] and, in concert
with nicotine, diminishes arterial distensibility in vivo [188].
Consequences of arteriosclerosis for ESRD patients
The most important consequence of arteriosclerosis is arterial
stiffening resulting in an increased left ventricular systolic stress
and an abnormal relationship between systolic and diastolic
tension-time integrals [3, 11, 13]. The principal consequences of
these alterations are left ventricular hypertrophy and altered
coronary perfusion with a decrease in subendocardial flow [11—
15].
The important factors relating the pressure load to LV hyper-
trophy and altered LV function are the peak and end-systolic
pressures in the aorta and central arteries, which are critically
dependent on arterial stiffness and the intensity and timing of
arterial wave reflections, that is, on the physical properties of
arteries [3, ii, 13]. Previous studies have shown that LV hyper-
trophy in ESRD was correlated to increased pulsatile pressure
load due to increased arterial stiffness and wave reflections [46,
167, 189]. Among ESRD patients, significant relations existed
between comparable cardiac and vascular parameters [169]. LV
diameter and arterial diameters are correlated and significant
correlations were observed between the common carotid artery
intima-media thickness and/or intima-media cross-sectional area
and LV wall thickness and/or LV mass (Fig. 8). These relation-
ships are independent of other factors like age, body surface area,
and gender [169]. Moreover, independently from the blood
pressure level, the extent of left ventricular hypertrophy is directly
proportional to the decrease in aortic distensibility (Fig. 7).
However, in ESRD patients a significant correlation was observed
between arterial diameter and LV diastolic diameter (Fig. 8), also
suggesting the existence of a direct link between arterial dilation
and LV hypertrophy [169]. Indeed, the inertial effects are greater
in enlarged arteries since larger blood-filled arteries require the
heart to produce excess work in order to accelerate blood against
larger inertial forces during ejection. An important consequence
of LVH is reduction of coronary reserve, and myocardial hyper-
trophy has long been known as a major factor in the pathogenesis
of myocardial ischemia.
The second most important consequence of arterial stiffening is
compromised coronary perfusion. Canine studies have shown that
aortic stiffening directly decreased subendocardial blood flow
despite an increase in mean coronary flow, and that chronic aortic
stiffening reduced cardiac transmural perfusion and aggravated
subendocardial ischemia [ii, 13, 14, 171]. Cardiac ischemia and
alterations in subendocardial perfusion are frequently observed in
uremic patients despite patent coronary arteries [20, 21]. This has
been recently shown in ESRD patients in which the changes in
large artery structure and function were associated with decreased
diastolic/systolic tension-time integral (subendocardial viability
index) (Fig. 9), an index of the propensity for myocardial ischemia
when there are altered hemodynamic forces in the absence of
occlusive arterial lesions [1691. Due to decreased arterial disten-
sibility and increased PWV, wave reflections return earlier and
impact on the incident wave during systole, increasing aortic and
CCA pressures, and increasing the LV systolic stress and the
systolic tension-time index, an index of LV oxygen and blood
demand. On the other hand, the impact of the reflected wave in
systole decreases the mean and telediastolic pressures, decreasing
the diastolic tension-time index, an index of LV perfusion capacity
[3, 13, 14]. Besides the role of abnormal structure and function of
aorta and major arteries, these alterations are partly related to
structural abnormalities of intramyocardial microvasculature. In
uremic rats, Amann et a! [190] have shown that diminished
myocardial capillary density and thickening of intramyocardial
arterioles are due to smooth muscle cell hyperplasia.
At this point of the discussion a special mention should be
made concerning the role of anemia in the pathogenesis of
arterial disorders and their clinical manifestation, By contributing
to maintain volume and flow overload, anemia is an important
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Fig. 8. Scatter plot showing the correlation
between the CCA intima-media cross sectional
area and interventricular septal thickness (A, r =
9 0.59, P < 0.0001) and CCA diameter and left
ventricular (LIZ) diastolic diameter (B; r = 0.39,
P < 0.0001) in ESRD patients (from London et
a!, Kidney mt 50:600—608, 1996, expanded data).
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factor in the pathogenesis of left ventricular hypertrophy and its
consequences [191—193]. Anemia induces an increased venous
return and left ventricular preload, and by contributing to arterial
remodeling also increases the ventricular afterload [169]. On the
other hand, anemia per se induces an alteration of the coronary
pressure-flow relationship, inducing an upward shift of the auto-
regulatory plateau and a decrease in coronary reserve. Therefore,
the nearly constant anemia in uremic patients, although it does
not appear to contribute per se to the development of ischemic
heart disease [155], plays an important role in the occurrence of
ischemic symptoms, whether or not in conjunction with the
presence of atheromatous plaques. This condition is frequently
underestimated or even ignored by cardiologists who take care of
such patients. Fortunately, the introduction of erythropoietin into
clinical practice has improved the therapeutic approach, and
myocardial hypertrophy generally regresses and myocardial isch-
emia may improve [191—193]. Nevertheless, it remains to be
determined whether the anemia should be entirely or only partly
corrected, since major changes of blood viscosity could alter the
shear stress applied to the vascular wall, with unpredictable
consequences.
Conclusion and perspectives
The cardiovascular complications of chronic renal failure pa-
tients can be schematically ascribed to two different major mech-
anisms: arteriosclerosis and atherosclerosis. Whereas the latter is
a disease that typically disturbs conduit function almost exclu-
sively, the former does not affect it. Most of the underlying
mechanisms and risk factors are different, however, some are
shared by the two conditions, including arterial hypertension,
hormonal disturbances, and dependence on growth factors.
Most of the factors that have been mentioned with respect to
the pathogenesis of arteriosclerosis, based on studies in the
general population, recently have been shown to play a similar
role in patients with end-stage renal disease. In contrast, several of
the above evoked mechanisms in the atherogenesis of chronic
renal failure remain hypothetical at present. One of the main
reasons is that no long-term, well-controlled studies have been
available in this area that would have systematically tested, in
uremic patients, the importance of factors such as high blood
pressure, via the use of antihypertensive drugs, or disturbances of
lipoprotein metabolism, via the use of lipid lowering medications.
Current clinical practice as to the use of the latter has been
extensively reviewed in a recent meta-analysis by Massy et al [194].
The majority of studies have been limited to relating hemody-
namic or metabolic parameters to parameters of ischemia. It is
only during recent years that a small number of controlled studies
has been conducted that were aimed at examining the effect of
antihypertensive drugs on static and dynamic parameters of the
vessel wall, in particular the pathologically increased arterial
stiffness [168, 195, 196]. Thus, London et al [196] could show that
the administration for 12 months of either the calcium channel
blocker, nitrendipine or the ACE inhibitor, perindopril led to a
decrease in arterial pulse wave velocity and pulse wave reflection,
indicative of an improvement of vessel wall elasticity. In addition,
the administration of perindopril, but not of nitrendipine, was
associated with a decrease in left ventricular myocardial mass,
primarily via a decrement of the left ventricular volume, although
both drugs led to an improvement of left ventricular function.
Controlled long-term studies are time and energy consuming,
but they are indispensable to reach valid conclusions on the
implications of the numerous factors which theoretically may play
a role in the ischemic syndromes of chronic renal failure patients.
This is also true for therapeutic interventions such as the use of
lipid lowering agents, vitamins, or dietary maneuvers. Prospective,
randomized, large-scale trials in uremic patients are urgently
required to answer this question.
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